KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares IssuedShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

BeOne Medicines (ONC) Change in Accured Expenses (2016 - 2025)

BeOne Medicines (ONC) has disclosed Change in Accured Expenses for 11 consecutive years, with $15.4 million as the latest value for Q4 2025.

  • On a quarterly basis, Change in Accured Expenses rose 122.19% to $15.4 million in Q4 2025 year-over-year; TTM through Dec 2025 was $19.0 million, a 227.83% increase, with the full-year FY2025 number at $19.0 million, up 227.83% from a year prior.
  • Change in Accured Expenses was $15.4 million for Q4 2025 at BeOne Medicines, up from $3.5 million in the prior quarter.
  • In the past five years, Change in Accured Expenses ranged from a high of $874.2 million in Q4 2022 to a low of -$190.2 million in Q4 2023.
  • A 5-year average of $48.8 million and a median of $1.7 million in 2022 define the central range for Change in Accured Expenses.
  • Peak YoY movement for Change in Accured Expenses: soared 1458.15% in 2023, then crashed 25217.43% in 2024.
  • BeOne Medicines' Change in Accured Expenses stood at $236.8 million in 2021, then soared by 269.2% to $874.2 million in 2022, then crashed by 121.76% to -$190.2 million in 2023, then soared by 63.48% to -$69.5 million in 2024, then skyrocketed by 122.19% to $15.4 million in 2025.
  • Per Business Quant, the three most recent readings for ONC's Change in Accured Expenses are $15.4 million (Q4 2025), $3.5 million (Q3 2025), and $52.4 million (Q2 2025).